Department of Cell Biology, School of Life Sciences, Shanghai University, Shanghai, PR China.
Stem Cells Dev. 2020 Jun 1;29(11):679-681. doi: 10.1089/scd.2020.0071. Epub 2020 Apr 17.
The novel coronavirus disease 2019 (COVID-19) has grown to be a global public-health emergency since patients were first detected in Wuhan, China, in December 2019. As of April 9, 2020, the novel coronavirus (named as SARS-CoV-2 by the International Committee on Taxonomy of Viruses on February 11) has infected 83,251 and 1,484,811 patients in China and the world, respectively. However, we have neither confirmed effective antiviral medications nor vaccines available to deal with this emergency. In this commentary, we offer an alternative promising therapy for COVID-19, that is, mesenchymal stem cell transplantation.
2019 年新型冠状病毒病（COVID-19）自 2019 年 12 月在中国武汉首次发现患者以来，已成为全球公共卫生紧急事件。截至 2020 年 4 月 9 日，新型冠状病毒（国际病毒分类委员会于 2 月 11 日命名为 SARS-CoV-2）已分别在中国和世界范围内感染了 83251 和 1484811 人。然而，我们既没有确认有效的抗病毒药物，也没有可用的疫苗来应对这一紧急情况。在这篇评论中，我们为 COVID-19 提供了一种有前途的替代治疗方法，即间充质干细胞移植。
